A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma

Trial Profile

A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs Ipilimumab (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 22 Jul 2015 Trial identifier 2011-000906-22 no longer appears in the European Clinical Trials Database.
    • 16 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 04 Nov 2013 Planned end date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top